Lower concentration of vitamin D is associated with lower DAS28 and VAS-pain scores in patients with inflammatory rheumatic diseases treated with infliximab: a pilot study

Miler, Marijana; Gabaj, Nora Nikolac; Grazio, Simeon; Vahtarić, Antonio; Vrtarić, Alen; Grubišić, Frane; Kavanagh, Hana Skala; Vajdić, Ines Doko; Vrkić, Nada

doi:10.1007/s00296-020-04607-3

Cited by 5 publications

(2 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, vitamin D deficiency in these patients can lead to a more severe and active course of the disease; thus, vitamin D serum level may be a predictive factor for one-year disability and disease progression (132,133). But not all evidence is in favor of the preventative effects of vitamin D. A recent study on RA patients concluded no significant differences between vitamin D-deficient and -nondeficient patients considering criteria such as swollen joints count (SJC), VAS-pain, tender joints count (TJC), and DAS28 scores (134). Further investigations can shed light on various features of the relationship between RA and vitamin D.…”

Section: Rheumatoid Arthritismentioning

confidence: 99%

Immunomodulatory actions of vitamin D in various immune-related disorders: a comprehensive review

Ghaseminejad-Raeini,

Ghaderi,

Sharafi

et al. 2023

Front. Immunol.

View full text Add to dashboard Cite

For many years, vitamin D has been acknowledged for its role in maintaining calcium and phosphate balance. However, in recent years, research has assessed its immunomodulatory role and come up with conflicting conclusions. Because the vitamin D receptor is expressed in a variety of immune cell types, study into the precise role of this molecule in diseases, notably autoimmune disorders, has been made possible. The physiologically activated version of vitamin D also promotes a tolerogenic immunological condition in addition to modulating innate and acquired immune cell responses. According to a number of recent studies, this important micronutrient plays a complex role in numerous biochemical pathways in the immune system and disorders that are associated with them. Research in this field is still relatively new, and some studies claim that patients with severe autoimmune illnesses frequently have vitamin D deficiencies or insufficiencies. This review seeks to clarify the most recent research on vitamin D’s immune system-related roles, including the pathophysiology of major disorders.

show abstract

Section: Rheumatoid Arthritismentioning

confidence: 99%

Immunomodulatory actions of vitamin D in various immune-related disorders: a comprehensive review

Ghaseminejad-Raeini,

Ghaderi,

Sharafi

et al. 2023

Front. Immunol.

View full text Add to dashboard Cite

show abstract

“…Data on the following variables were recorded at the time of IFX initiation (baseline) and week 54, including 1) patient characteristics: age, gender, smoking status and body mass index (BMI); 2) disease characteristics: disease extent, disease behavior, disease activity (assessed by HBI), prior surgical history and medications (including biologic agents, glucocorticoid, immunomodulators, and vitamin D agents); 3) biochemical parameters: hemoglobin (Hb), platelet (PLT), C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), albumin (Alb), as well as serum concentration of calcium and phosphorus; 4) serum concentration of 25-hydroxyvitamin D [25(OH)D], which was a routine test item in our hospital for assessment of CD disease activity. The cut-off concentration for vitamin D de ciency was taken from the de nition of the Endocrine Society Recommendations: patients with 25(OH)D below 20 ng/mL were considered de cient, while those with 25(OH)D ≥ 20 ng/mL were considered non-de cient [21].…”

Section: Data Collectionmentioning

confidence: 99%

Influence of Vitamin D3 Supplementation On Infliximab Effectiveness in Chinese Patients With Crohn’s Disease: A Retrospective Cohort Study

Xia

Min

Shao

et al. 2021

Preprint

View full text Add to dashboard Cite

Background: It remains uncertain whether vitD3 supplementation is beneficial for remission of Crohn’s disease (CD). The influence of vitD3 supplementation on Infliximab (IFX) effectiveness was analyzed in Chinese CD patients.Methods: In this retrospective cohort study, moderate-to-severe CD patients, who were bio-naïve and prescribed with IFX treatment for at least 54 weeks, were recorded from January 2014 to December 2019. VitD3 supplementation was defined as patients additionally took oral vitD3 (125 IU/d) within 3 days after the first infusion and persisted in the whole follow-up period. Disease activity was assessed using Harvey-Bradshaw Index (HBI). Serum cytokine profiles (IL-2, IL-4, IL-6, IL-10, TNF-α and IFN-γ) were quantitatively analyzed in a subset of all patients at baseline and 54-week after intervention.Results: Among 73 enrolled patients, 37 took vitD3 regularly (D3-patients), the others (non-D3-patients) did not. At 54-week, the mean 25-hydroxyvitaminD level increased in D3-patients (20.33 ng/mL vs. 15.07 ng/mL, P<0.001). The clinical remission rate was higher in D3-patients compared to non-D3-patients (83.8% vs. 61.6%, P=0.030). The decrease of HBI from baseline to 54-week was more in D3-patients than non-D3-patients (7.41±3.0 vs. 6.28±2.75, P=0.023). Furthermore, vitD3 supplementation was independently related to the increase of remission rate at 54-week in D3-patients (β=-1.667, P=0.015). The benefit of vitD3 supplementation was significant only in patients with deficient vitD3 (all P<0.05), but not in non-deficient vitD3. In non-D3-patients, the decreases of TNF-α and IL-6 at 54-week were more obvious than at baseline (P=0.032, 0.022, respectively). In D3-patients, however, only IL-10 increased at 54-week compared with its baseline value (P=0.037).Conclusions: VitD3 supplementation could not only improve IFX effectiveness, especially for patients with vitD3 deficiency, but also affected the cytokine profiles in CD patients.Trial registration: NCT04606017.

show abstract

Association of polymorphisms in promoter region of TNF-α -238 and -308 with clinical outcomes in patients with immune-mediated inflammatory diseases on anti-TNF therapy

Miler¹,

Gabaj

Ćelap³

et al. 2021

Rheumatol Int

View full text Add to dashboard Cite

Lower concentration of vitamin D is associated with lower DAS28 and VAS-pain scores in patients with inflammatory rheumatic diseases treated with infliximab: a pilot study

Cited by 5 publications

References 28 publications

Immunomodulatory actions of vitamin D in various immune-related disorders: a comprehensive review

Immunomodulatory actions of vitamin D in various immune-related disorders: a comprehensive review

Influence of Vitamin D3 Supplementation On Infliximab Effectiveness in Chinese Patients With Crohn’s Disease: A Retrospective Cohort Study

Association of polymorphisms in promoter region of TNF-α -238 and -308 with clinical outcomes in patients with immune-mediated inflammatory diseases on anti-TNF therapy

Contact Info

Product

Resources

About